Stock listing

TASE:PPBT Purple Biotech Ltd. מניה‎

Home listing (TASE) of Purple Biotech Ltd.

Follow Purple Biotech Ltd. into a list and get an email when it puts out news.

Share price · TASE:PPBT

1.00 ILA (agorot) 0.00 (0.0%)

Close on Nov 19, 2026

Past year -16.7% · daily closes, Nov 19, 2025 – Nov 19, 2026, adjusted for splits
Day range
1.00 – 1.00 ILA (agorot)Nov 19, 2026
Market cap
32.54M ILSAt the close on Nov 19, 2026 · price × 3.25B shares outstanding
52-week range
1.00 – 1.60 ILA (agorot)Lowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
157 ILSMedian day 0 shares · 54 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
Purple Biotech Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TASE:PPBT · Home1.00 ILA (agorot)0.00 (0.0%)—1.001.001.001.00Close on Nov 19, 2026
NASDAQ:PPBT$1.525 USD-0.005 (-0.3%)21,776$1.50$1.56$1.29$1.53Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TASE:PPBT · ILA (agorot), adjusted for splits

DayCloseChange%OpenHighLowVolume
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.00100,000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.00250,000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.00100,000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.0050,000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.0011,000
1.000.000.0%1.001.001.00150,000
1.000.000.0%1.001.001.00300,000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.0030,000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.001,000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000
1.000.000.0%1.001.001.000

Splits

3 splits since 2012 · TASE:PPBT · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-13Consolidation
1-for-100Consolidation
Ticker
TASE:PPBT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
TASE
Currency
ILA

What changed lately

Latest news

All Purple Biotech Ltd. news

Purple Biotech Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
9 in the last 12 months · 32 in all · newest Apr 27, 2026 · oldest 2025
Decks
56 decks · latest Aug 10, 2026

Where Purple Biotech Ltd. is listed

ListingExchangeCountryCurrency
TASE:PPBT · Home listing · This pageTASEIsraelILA
NASDAQ:PPBTNASDAQUnited StatesUSD
BOATS:PPBTBOATSUnited StatesUSD
gettex:1YI0gettexGermanyEUR
Frankfurt:1YI0FrankfurtGermanyEUR
Lang & Schwarz:A40NWELang & SchwarzGermanyEUR
Munich:1YI0MunichGermanyEUR
Stuttgart:IL0007650166StuttgartGermanyEUR

Valuation

Price/book 0.8× against a median of 0.6×: 5th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 19, 2026

Enterprise value
12.50M ILS
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.8×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Purple Biotech Ltd. · TASE:PPBTUS$9.70MUS$3.73Mn/an/an/a0.8×n/a0.0×n/a
Ceryvyn Therapeutics Limited · ASX:CYVUS$9.96M−US$9.91M0.1×−14,971×n/a0.5×n/a0.0×n/a
aTyr Pharma, Inc. · NASDAQ:ATYRUS$9.74M−US$28.09Mn/an/an/a0.3×n/a0.3×2.12
Lisata Therapeutics, Inc. · NASDAQ:LSTAUS$9.71M−US$273.0Mn/a−2,730×n/a1.3×n/a0.0×0.71
Jasper Therapeutics, Inc. · NASDAQ:JSPRUS$9.64M−US$125.6Mn/a−15.7×n/an/an/an/a2.02
Chemomab Therapeutics Ltd. · NASDAQ:CMMBUS$9.58MUS$4.92Mn/an/an/a2.6×n/a0.0×1.04
Alzinova AB · OMXSTO:ALZUS$9.57MUS$8.34Mn/a17.0×n/a0.6×−484.4%0.0×n/a
Genvor Incorporated · OTC:GNVRUS$9.47MUS$9.27Mn/an/an/an/an/an/a0.44
Poxel SA · EURONEXT:POXELUS$9.27MUS$73.95Mn/an/an/an/an/an/an/a
TScan Therapeutics, Inc. · NASDAQ:TCRXUS$9.27M−US$30.80Mn/a−5.9×n/a0.2×n/a0.9×1.66
Rapid Dose Therapeutics Corp · CSE:DOSEUS$9.13MUS$9.12Mn/a5.1×n/an/a−123.1%n/a0.64
Median of the othersUS$9.57M−US$2.49M0.1×−10.8×0.6×−303.7%0.0×1.04

Team and board

Officers

OfficerRole
Isaac IsraelInterim Chief Executive Officer
Shai LankryChief Financial Officer
Hadas ReuveniVice President Research & Development
Michael SchicklerHead of Clinical and Regulatory Affairs

Board

DirectorRole
Eric RowinskyChairman of the Board
Ido AgmonBoard Member
Isaac IsraelInterim Chief Executive Officer
Robert GagnonBoard Member
Suzana Nahum-ZilberbergBoard Member
Yael MargolinBoard Member

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck45 slidesAug 10, 2026
Investor Presentation (June 2026)Investor deck45 slidesJun 23, 2026
Investor Presentation (March 2026)Investor deck59 slidesMar 19, 2026
Investor Presentation (January 2026)Investor deck62 slidesJan 13, 2026
Investor Presentation (January 2026)Investor deck59 slidesJanuary 2026
Investor Presentation (November 2025)Investor deck57 slidesNov 19, 2025
Investor Presentation (September 2025)Investor deck56 slidesSep 16, 2025
Investor Presentation (July 2025)Investor deck55 slidesJuly 2025
Investor Presentation (May 2025)Investor deck59 slidesMay 6, 2025
Investor Presentation (March 2025)Investor deck58 slidesMar 18, 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (March 2025)Investor deck59 slidesMarch 2025
Investor Presentation (December 2024)Investor deck57 slidesDec 6, 2024
Investor Presentation (October 2024)Investor deck54 slidesOct 9, 2024
Investor Presentation (August 2024)Investor deck53 slidesAugust 2024
Investor Presentation (July 2024)Investor deck53 slidesJul 19, 2024
Investor Presentation (July 2024)Investor deck53 slidesJuly 2024
Investor Presentation (June 2024)Investor deck52 slidesJun 4, 2024
Investor Presentation (May 2024)Investor deck44 slidesMay 2, 2024
Investor Presentation (March 2024)Investor deck43 slidesMarch 2024
Investor Presentation (November 2023)Investor deck42 slidesNovember 2023
Investor Presentation (October 2023)Investor deck43 slidesOct 13, 2023
Investor Presentation (September 2023)Investor deck44 slidesSep 13, 2023
Investor Presentation (September 2023)Investor deck44 slidesSeptember 2023
Investor Presentation (March 2023)Investor deck45 slidesMarch 2023
Investor Presentation (February 2023)Investor deck45 slidesFeb 3, 2023
Investor Presentation (February 2023)Investor deck45 slidesFebruary 2023
Investor Presentation (January 2023)Investor deck41 slidesJan 6, 2023
Investor Presentation (January 2023)Investor deck41 slidesJanuary 2023
Investor Presentation (November 2022)Investor deck41 slidesNov 9, 2022
Jefferies London Healthcare Conference 2022Conference41 slidesNovember 2022
Investor Presentation (September 2022)Investor deck41 slidesSeptember 2022
Investor Presentation (August 2022)Investor deck41 slidesAugust 2022
Investor Presentation (June 2022)Investor deck41 slidesJune 2022
Investor Presentation (February 2022)Investor deck36 slidesFebruary 2022
Investor Presentation (November 2021)Investor deck37 slidesNovember 2021
Investor Presentation (September 2021)Investor deck37 slidesSeptember 2021
Investor Presentation (August 2021)Investor deck41 slidesAugust 2021
Investor Presentation (June 2021)Investor deck42 slidesJune 2021
Investor Presentation (March 2021)Investor deck40 slidesMarch 2021
Investor Presentation (January 2021)Investor deck40 slidesJanuary 2021
Kitov Pharma — Investor Presentation (November 2020)Investor deck39 slidesNov 12, 2020
Kitov Pharma — Investor Presentation (May 2020)Investor deck39 slidesMay 4, 2020
Kitov Pharma — Investor Presentation (October 2019)Investor deck45 slidesOct 18, 2019
Kitov Pharma — Investor Presentation (September 2019)Investor deck46 slidesSep 10, 2019
Kitov Pharma — 18th MIXiii-Biomed Conference and Exhibition 2019Conference16 slidesMay 16, 2019
Kitov Pharma — Investor Presentation (April 2019)Investor deck19 slidesApr 15, 2019
Kitov Pharma — Investor Presentation (February 2019)Investor deck26 slidesFeb 11, 2019
Kitov Pharmaceuticals Holdings — Investor Presentation (November 2017)Investor deck27 slidesNov 29, 2017
Kitov Pharmaceuticals Holdings — Investor Presentation (June 2017)Investor deck27 slidesJun 15, 2017
Kitov Pharmaceuticals Holdings — Investor Presentation (January 2017)Investor deck13 slidesJan 23, 2017

This page holds 50 of 56 decks. Open Decks

Open Decks

Financings

RaiseDate
Public offering of american Depositary Shares (or pre-funded warrants) and short-term warrants
Closed: US$6M raised · US$1 a share · Warrants at US$1 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Development of its oncology therapeutic candidates and general working capital and corporate purposes
Sep 5, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Kitov Pharmaceuticals Holdings Ltd. Priced at US$4.12 an ADS on Nov 23, 2015.

Price
US$4.12 an ADS
ADSs offered
3,158,900 American depositary shares
Offering size
US$13 million
Underwriters' option
Up to 473,835 more ADSs
Listing
KTOV on the Nasdaq Capital Market
Underwriters
Rodman & Renshaw, Joseph Gunnar & Co. · In the order on the cover
ADSs delivered
On or about Nov 25, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceAug 18, 2014
Filed publiclySep 24, 2015
Amended 4 timesNewest Nov 20, 2015
Shares registered with an exchangeNov 18, 2015
Declared effective by the SECNov 20, 2015
Final prospectus, with the priceNov 23, 2015

Open IPO · From the cover of the final prospectus (424B4) filed Nov 23, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00195.8K001.00M1.00M1.00M100.0K
Cost of revenue219.7K62.0K196.0K120555880
Gross profit-219.7K-62.0K-196-120-55999.9K999.9K1.00M
Research and development3.73M7.62M17.0M16.3M11.8M7.24M2.28M5.27M4.64M4.18M
Selling, general and administrative3.25M3.18M5.24M6.28M6.11M6.00M4.39M5.20M6.40M3.00M
Operating income-27.5M-11.0M-22.3M-22.6M-17.9M-12.6M-7.16M-7.83M-12.0M-7.18M
Depreciation and amortization203.0K186.0K197.0K201.0K231.0K235.0K178.0K7.00K4.00K2.00K
EBITDA-27.3M-10.8M-22.1M-22.4M-17.7M-12.4M-6.98M-7.82M-12.0M-7.18M
Interest expense982.0K483.0K2.19M67.0K-212.0K61.0K181.0K576.0K26.0K61.0K
Income before tax-26.5M-7.28M-20.0M-21.8M-17.8M-28.7M-5.89M-5.57M
Income tax216.0K
Net income-26.4M-7.24M-19.9M-21.7M18.4M28.0M5.85M5.20M12.2M12.1M
Earnings per share, basic0.034.4417.9623.9717,568,036.000.160.300.37
Earnings per share, diluted0.034.9917.9623.9717,568,036.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents8.72M7.40M14.5M15.0M10.9M11.2M4.38M5.16M3.95M6.76M
Short-term investments857.2K275.0K73.0K431.0K36.3M46.6M2.01M1.52M
Receivables155.0K275.0K500.0K1.49M743.0K
Inventory-1.49M778.0K
Current assets9.87M8.91M15.8M33.3M48.5M59.3M8.30M8.51M7.98M14.9M
Property, plant and equipment124.0K124.0K154.0K215.0K277.0K178.0K38.0K37.0K28.0K16.0K
Goodwill20.7M20.5M20.5M
Total assets17.6M37.0M44.3M54.6M70.2M83.8M14.7M14.7M14.2M14.9M
Accounts payable2.07M1.46M3.53M2.13M1.47M1.20M1.25M705.0K215.0K515.0K
Current liabilities7.75M3.99M9.70M7.06M4.25M3.10M3.55M3.31M3.97M1.27M
Total debt244.1K183.0K351.0K515.0K749.0K895.0K223.0K
Total liabilities7.91M4.13M10.0M7.52M5.09M4.05M3.86M3.72M
Shareholders' equity9.71M32.9M34.2M46.9M64.8M79.4M10.4M10.5M7.41M13.4M
Shares outstanding960.1M517.1M246.2M184.8M178.0M172.1M19.4M14.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-5.66M-14.4M-19.9M-16.7M-374.0K1.71M-1.97M-8.48M-8.63M-6.26M
Capital spending-3.00K0-3.00K-26.0K-115.0K-156.0K-11.0K-16.0K-13.0K-10.0K
Free cash flow-5.66M-14.4M-19.9M-16.8M-489.0K1.55M-1.98M-8.50M-8.64M-6.27M
Cash from investing632.0K509.0K13.9M19.9M13.4M-49.6M-449.0K2.04M2.77M-7.77M
Cash from financing6.33M6.77M5.45M1.11M1.51M68.5M5.23M7.79M3.00M10.3M
Dividends paid00000000
Change in cash1.31M-7.08M-595.0K4.29M-333.0K6.80M-797.0K1.35M-2.86M-3.75M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 20, 2026Current reportSEC
6-K · Report of a foreign issuerNov 17, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveNov 12, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
F-3/A · Registration statement, amendedNov 6, 2026Offer documentSEC
6-K · Report of a foreign issuerOct 5, 2026Current reportSEC
6-K · Report of a foreign issuerSep 9, 2026Current reportSEC
6-K · Report of a foreign issuerSep 2, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerAug 10, 2026Current reportSEC
6-K · Report of a foreign issuerAug 7, 2026Current reportSEC
6-K · Report of a foreign issuerJul 29, 2026Current reportSEC
6-K · Report of a foreign issuerJun 23, 2026Current reportSEC
6-K · Report of a foreign issuerJun 11, 2026Current reportSEC
F-3 · Registration statementMay 20, 2026Offer documentSEC
6-K · Report of a foreign issuerMay 15, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerApr 27, 2026Current reportSEC
6-K · Report of a foreign issuerApr 23, 2026Current reportSEC
3 · Initial statement of ownershipApr 17, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 7, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 6, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
3/A · Initial statement of ownership, amendedMar 30, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 30, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 25, 2026Current reportSEC
6-K · Report of a foreign issuerMar 18, 2026Current reportSEC
20-F · Annual reportMar 18, 2026Annual reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 17, 2026Current reportSEC
6-K · Report of a foreign issuerMar 13, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 25, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerJan 12, 2026Current reportSEC
6-K · Report of a foreign issuerJan 7, 2026Current reportSEC
6-K · Report of a foreign issuerDec 16, 2025Current reportSEC
6-K · Report of a foreign issuerDec 11, 2025Current reportSEC
6-K · Report of a foreign issuerNov 19, 2025Current reportSEC
6-K · Report of a foreign issuerNov 14, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerOct 29, 2025Current reportSEC
6-K · Report of a foreign issuerOct 28, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
6-K · Report of a foreign issuerSep 19, 2025Current reportSEC
424B5 · ProspectusSep 19, 2025Offer documentSEC
6-K · Report of a foreign issuerSep 15, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 10, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerSep 10, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 9, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 9, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 9, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerSep 5, 2025Current reportSEC
424B4 · ProspectusSep 5, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 5, 2025Other filingsSEC
6-K · Report of a foreign issuerSep 4, 2025Current reportSEC
6-K · Report of a foreign issuerSep 3, 2025Current reportSEC
CORRESP · Letter to the SECAug 29, 2025Other filingsSEC
CORRESP · Letter to the SECAug 29, 2025Other filingsSEC
F-1 · Registration statementAug 29, 2025Offer documentSEC
6-K · Report of a foreign issuerAug 6, 2025Current reportSEC
6-K · Report of a foreign issuerJul 23, 2025Current reportSEC
UPLOAD · Letter from the SECJul 15, 2025Other filingsSEC
6-K · Report of a foreign issuerJul 10, 2025Current reportSEC
DRS · Draft registration statementJul 10, 2025Offer documentSEC
6-K · Report of a foreign issuerJun 23, 2025Current reportSEC
6-K · Report of a foreign issuerJun 17, 2025Current reportSEC
6-K · Report of a foreign issuerMay 21, 2025Current reportSEC
6-K · Report of a foreign issuerMay 12, 2025Current reportSEC
6-K · Report of a foreign issuerMay 6, 2025Current reportSEC
6-K · Report of a foreign issuerApr 30, 2025Current reportSEC
6-K · Report of a foreign issuerApr 28, 2025Current reportSEC
6-K · Report of a foreign issuerApr 22, 2025Current reportSEC
6-K · Report of a foreign issuerApr 16, 2025Current reportSEC
6-K · Report of a foreign issuerApr 15, 2025Current reportSEC
6-K · Report of a foreign issuerApr 1, 2025Current reportSEC
6-K · Report of a foreign issuerMar 28, 2025Current reportSEC
6-K · Report of a foreign issuerMar 18, 2025Current reportSEC
20-F · Annual reportMar 10, 2025Annual reportSEC
6-K/A · Report of a foreign issuer, amendedMar 10, 2025Current reportSEC
6-K · Report of a foreign issuerMar 10, 2025Current reportSEC
6-K · Report of a foreign issuerMar 5, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 3, 2025Current reportSEC
6-K · Report of a foreign issuerJan 6, 2025Current reportSEC
424B5 · ProspectusJan 6, 2025Offer documentSEC
6-K · Report of a foreign issuerDec 6, 2024Current reportSEC
6-K · Report of a foreign issuerDec 5, 2024Current reportSEC
6-K · Report of a foreign issuerDec 4, 2024Current reportSEC
424B5 · ProspectusDec 4, 2024Offer documentSEC
6-K · Report of a foreign issuerDec 3, 2024Current reportSEC
6-K · Report of a foreign issuerDec 2, 2024Current reportSEC
6-K · Report of a foreign issuerNov 15, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerNov 4, 2024Current reportSEC
6-K · Report of a foreign issuerOct 25, 2024Current reportSEC
6-K · Report of a foreign issuerOct 10, 2024Current reportSEC
6-K · Report of a foreign issuerOct 9, 2024Current reportSEC
6-K · Report of a foreign issuerOct 2, 2024Current reportSEC
6-K · Report of a foreign issuerSep 18, 2024Current reportSEC
6-K · Report of a foreign issuerSep 11, 2024Current reportSEC
6-K · Report of a foreign issuerAug 19, 2024Current reportSEC
6-K · Report of a foreign issuerAug 16, 2024Current reportSEC
6-K · Report of a foreign issuerAug 8, 2024Current reportSEC
6-K · Report of a foreign issuerAug 5, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveJul 31, 2024Other filingsSEC
424B3 · ProspectusJul 30, 2024Offer documentSEC
CORRESP · Letter to the SECJul 26, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 26, 2024Other filingsSEC
6-K · Report of a foreign issuerJul 25, 2024Current reportSEC
F-1 · Registration statementJul 22, 2024Offer documentSEC
6-K · Report of a foreign issuerJul 19, 2024Current reportSEC
DJul 15, 2024Other filingsSEC
424B3 · ProspectusJul 2, 2024Offer documentSEC
6-K · Report of a foreign issuerJul 2, 2024Current reportSEC
6-K · Report of a foreign issuerJul 2, 2024Current reportSEC
6-K · Report of a foreign issuerJul 1, 2024Current reportSEC
6-K · Report of a foreign issuerJun 27, 2024Current reportSEC
6-K · Report of a foreign issuerJun 26, 2024Current reportSEC
6-K · Report of a foreign issuerJun 20, 2024Current reportSEC
6-K · Report of a foreign issuerJun 4, 2024Current reportSEC
6-K · Report of a foreign issuerJun 3, 2024Current reportSEC
6-K · Report of a foreign issuerMay 21, 2024Current reportSEC
6-K · Report of a foreign issuerMay 2, 2024Current reportSEC
6-K · Report of a foreign issuerApr 25, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveApr 3, 2024Other filingsSEC
POS AM · Amendment to an effective registrationMar 28, 2024Offer documentSEC
6-K · Report of a foreign issuerMar 28, 2024Current reportSEC
6-K · Report of a foreign issuerMar 14, 2024Current reportSEC
6-K · Report of a foreign issuerMar 6, 2024Current reportSEC
20-F · Annual reportMar 5, 2024Annual reportSEC
6-K · Report of a foreign issuerMar 5, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 27, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 13, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 1, 2024Current reportSEC
6-K · Report of a foreign issuerJan 26, 2024Current reportSEC
6-K · Report of a foreign issuerDec 20, 2023Current reportSEC
6-K · Report of a foreign issuerDec 14, 2023Current reportSEC
6-K · Report of a foreign issuerNov 21, 2023Current reportSEC
6-K · Report of a foreign issuerNov 21, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveNov 15, 2023Other filingsSEC
424B3 · ProspectusNov 14, 2023Offer documentSEC
CORRESP · Letter to the SECNov 13, 2023Other filingsSEC
F-1/A · Registration statement, amendedNov 13, 2023Offer documentSEC
6-K · Report of a foreign issuerNov 2, 2023Current reportSEC
DOct 31, 2023Other filingsSEC
F-1 · Registration statementOct 30, 2023Offer documentSEC
424B3 · ProspectusOct 19, 2023Offer documentSEC
6-K · Report of a foreign issuerOct 19, 2023Current reportSEC
6-K · Report of a foreign issuerOct 19, 2023Current reportSEC
424B5 · ProspectusOct 19, 2023Offer documentSEC
6-K · Report of a foreign issuerOct 17, 2023Current reportSEC
424B5 · ProspectusOct 17, 2023Offer documentSEC
6-K · Report of a foreign issuerOct 13, 2023Current reportSEC
6-K · Report of a foreign issuerOct 6, 2023Current reportSEC
6-K · Report of a foreign issuerOct 3, 2023Current reportSEC
6-K · Report of a foreign issuerSep 21, 2023Current reportSEC
6-K · Report of a foreign issuerSep 13, 2023Current reportSEC
6-K · Report of a foreign issuerAug 22, 2023Current reportSEC
6-K · Report of a foreign issuerJul 11, 2023Current reportSEC
6-K/A · Report of a foreign issuer, amendedJun 20, 2023Current reportSEC
6-K · Report of a foreign issuerJun 15, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveMay 23, 2023Other filingsSEC
6-K · Report of a foreign issuerMay 22, 2023Current reportSEC
CORRESP · Letter to the SECMay 18, 2023Other filingsSEC
F-3/A · Registration statement, amendedMay 17, 2023Offer documentSEC
6-K · Report of a foreign issuerMay 16, 2023Current reportSEC
6-K · Report of a foreign issuerMay 1, 2023Current reportSEC
6-K · Report of a foreign issuerApr 25, 2023Current reportSEC
6-K · Report of a foreign issuerApr 19, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveApr 6, 2023Other filingsSEC
424B3 · ProspectusApr 5, 2023Offer documentSEC
CORRESP · Letter to the SECApr 3, 2023Other filingsSEC
424B3 · ProspectusApr 3, 2023Offer documentSEC
UPLOAD · Letter from the SECMar 30, 2023Other filingsSEC
6-K · Report of a foreign issuerMar 24, 2023Current reportSEC
F-3 · Registration statementMar 23, 2023Offer documentSEC
6-K · Report of a foreign issuerMar 16, 2023Current reportSEC
20-F · Annual reportMar 3, 2023Annual reportSEC
6-K · Report of a foreign issuerFeb 14, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 8, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 3, 2023Current reportSEC
6-K · Report of a foreign issuerFeb 2, 2023Current reportSEC
6-K · Report of a foreign issuerJan 6, 2023Current reportSEC
6-K · Report of a foreign issuerJan 3, 2023Current reportSEC
UPLOAD · Letter from the SECDec 12, 2022Other filingsSEC
F-3 · Registration statementDec 7, 2022Offer documentSEC
6-K · Report of a foreign issuerNov 15, 2022Current reportSEC
6-K · Report of a foreign issuerNov 9, 2022Current reportSEC
6-K · Report of a foreign issuerNov 8, 2022Current reportSEC
6-K · Report of a foreign issuerNov 2, 2022Current reportSEC
6-K · Report of a foreign issuerAug 25, 2022Current reportSEC
6-K · Report of a foreign issuerAug 4, 2022Current reportSEC
6-K · Report of a foreign issuerJul 18, 2022Current reportSEC
6-K · Report of a foreign issuerJul 14, 2022Current reportSEC
6-K · Report of a foreign issuerJun 6, 2022Current reportSEC
6-K · Report of a foreign issuerMay 27, 2022Current reportSEC

This page holds 200 of 582 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Purple Biotech Ltd.’s releases · as of Sep 5, 2025

Common shares
3,253,734,117
Fully diluted
3,253,734,117

Fully diluted

LineShares
Common shares3,253,734,117

Warrants and options

Lot
Warrants · US$1.00 · expire about Sep 2027

Share count over time

CountShares
Nov 22, 20263,253,734,117

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
SmartHarvest Portfolios, LLC51,267US$77,926Sep 30, 2026
Hrt Financial LP18,229US$27,000Sep 30, 2026
Jane Street14,003US$21,285Sep 30, 2026
UBS6,472US$9,837Sep 30, 2026
Rhumbline Advisers850US$1,291Sep 30, 2026
BNP Paribas400US$608Sep 30, 2026
Morgan Stanley300US$456Sep 30, 2026
RBC118Sep 30, 2026
Caitong International Asset Management Co., Ltd78US$119Sep 30, 2026
Northwestern Mutual Wealth Management Co8US$12Sep 30, 2026
All 12 holders
HolderSharesValueAs of
IFG Advisory, LLC7US$11Sep 30, 2026
SBI Securities Co., Ltd.4US$6Sep 30, 2026

Funds

HolderSharesValueAs of
Blackstone Alternative Multi-Strategy Fund10US$17Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Ayrton Capital LLC9.99%103KSep 30, 2026Schedule 13G
Mitchell P. Kopin9.99%207MSep 30, 2026Schedule 13G
Lincoln Alternative Strategies LLC9.90%605KSep 4, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Robert Gagnon
Other companies: Opus Genetics, Inc. (Chief Financial Officer · Since at least Sep 2, 2025); Bone Biologics Corp (Director · Since at least Jan 8, 2024); Verastem, Inc. (Director · Since at least Aug 28, 2018); Harvard Bioscience, Inc. (Director · Since at least Nov 18, 2013); Clean Harbors, Inc. (EVP CFO and Treasurer · Aug 20, 2012 – Sep 11, 2012 · Past); Biogen Inc. (Vice President, Finance · Nov 3, 2010 – Feb 28, 2012 · Past)
Board Member · Since at least Mar 18, 2026
Eric K. Rowinsky
Other companies: Verastem, Inc. (Director · Since at least Jun 21, 2019); Biogen Inc. (Director · Since at least Jun 19, 2019); Fortress Biotech, Inc. (Director · Jan 1, 2019 – Jan 1, 2024 · Past)
Chairman of the Board · Since at least Mar 13, 2026
Gil EfronExecutive Director, Head of Corporate Development · Until Mar 13, 2026 · Past
Gil EfronChief Executive Officer · Since at least Mar 18, 2026
Hadas ReuveniVice President Research & Development · Since at least Dec 11, 2025
Ido AgmonBoard Member · Since at least Mar 18, 2026
Isaac IsraelInterim Chief Executive Officer · Since at least Nov 6, 2026
Michael SchicklerHead of Clinical and Regulatory Affairs · Since at least Oct 29, 2025
Shai LankryChief Financial Officer · Since at least May 12, 2025
Suzana Nahum-ZilberbergBoard Member · Since at least Nov 6, 2026
All 11 people
PersonSeat
Yael MargolinBoard Member · Since at least Nov 6, 2026

Open People

Log in to ask 6ix AI your own questions about Purple Biotech Ltd.